PFM Health Sciences’s Iovance Biotherapeutics IOVA Stock Holding History

PFM Health Sciences’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-132,152	Closed	-$440K	–	66
2025 Q1	$440K	Hold	132,152	–	–	0.03%	64
2024 Q4	$978K	Hold	132,152	–	–	0.06%	77
2024 Q3	$1.24M	Sell	132,152 -20,643	-14%	-$196K	0.07%	71
2024 Q2	$1.23M	Sell	152,795 -157,959	-51%	-$1.69M	0.06%	74
2024 Q1	$4.61M	Buy	+310,754	New	+$3.62M	0.22%	69
2023 Q3	–	Sell	-946,305	Closed	-$6.66M	–	79
2023 Q2	$6.66M	Buy	946,305 +804,250	+566%	+$5.76M	0.26%	68
2023 Q1	$868K	Buy	142,055 +128,718	+965%	+$888K	0.04%	77
2022 Q4	$85.2K	Buy	+13,337	New	+$104K	﹤0.01%	89
2020 Q4	–	Sell	-381,990	Closed	-$15.2M	–	92
2020 Q3	$12.6M	Buy	+381,990	New	+$11.7M	0.58%	56

Other funds holding IOVA

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PFM Health Sciences's IOVA Position: Q2 2025 in Review

PFM Health Sciences sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 132,152 shares — an estimated $440K sold.

PFM Health Sciences first reported a position in IOVA in Q3 2020 and held it in 9 quarters. The position peaked at $12.6M in Q3 2020. 254 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

PFM Health Sciences reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
PFM Health Sciences sold 132,152 Iovance Biotherapeutics shares in Q2 2025, an estimated $440K.
PFM Health Sciences first reported a position in Iovance Biotherapeutics in Q3 2020 and held it in 9 quarters.
PFM Health Sciences's Iovance Biotherapeutics position peaked at $12.6M in Q3 2020.
254 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on PFM Health Sciences's 13F filing for Q2 2025, filed 14 Aug 2025.